## Background: The objective of this study was to identify clinical, biochemical, ultrasound, and/or pathologic parameters capable of predicting survival in a cohort of patients with well compensated cirrhosis and small hepatocellular carcinoma (hcc) who were treated with percutaneous ethanol injec
Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Analysis of prognostic factors in 105 western patients
β Scribed by Riccardo Lencioni; Carlo Bartolozzi; Davide Caramella; Alessandro Paolicchi; Mario Carrai; Giacomo Maltinti; Alfonso Capria; Alessandro Tafi; Pier Franco Conte; Generoso Bevilacqua
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 921 KB
- Volume
- 76
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
Background:
Percutaneous ethanol injection (pei) has been used in the far east for treating small, unresectable hepatocellular carcinoma (hcc). to clarify when treatment with pei may be best indicated for western patients with hcc, the authors performed a retrospective analysis of the clinicopathologic factors influencing prognosis.
Methods:
From december 1987 to august 1994, 105 patients with cirrhosis with hcc received pei as the sole anticancer treatment. eighty-two patients had uninodular tumors smaller than 5 cm, and 23 patients had multiple lesions (2-4) smaller than or equal to 3 cm each. all patients were in child-pugh class a (n = 64) or b (n = 41). survival was analyzed according to patient- and tumor-related factors by means of the kaplan-meier method.
Results:
The estimated survival rates of all 105 patients were 96% at 1 year, 86% at 2 years, 68% at 3 years, 51% at 4 years, 32% at 5 years, and 24% at 6 years. survival was not affected by sex, age, etiology of cirrhosis, or hepatitis b surface antigen or anti-hepatitis c virus positivity, but depended on child-pugh class (p = 0.006) and presence of ascites (p = 0.009). patients with a pretreatment alpha-fetoprotein level of 200 ng/ml or less had a better prognosis than patients with an alpha-fetoprotein level higher than 200 ng/ml (p = 0.007). patients with unmodular hcc of 3 cm or less had significantly better long term survival (p = 0.04) than patients with uninodular hcc of 3.1-5 cm or with multinodular tumors. tumor grade according to edmondson and steiner and tumor volume, in contrast, did not significantly influence prognosis (p > 0.1).
Conclusions:
For western patients with hcc treated with pei, the prognosis was highly dependent on the severity of the underlying cirrhosis. treatment with pei is best indicated for patients with uninodular tumors of 3 cm or less in greatest dimension and an alpha-fetoprotein level lower than 200 ng/ml.
π SIMILAR VOLUMES
This study was intended to compare the survival rates of two contemporary cohorts of patients with solitary hepatocellular carcinomas 5 4 cm subjected to surgical resection (n = 33) or percutaneous ethanol injection (n = 30). Outcomes in a third cohort, 21 patients with hepatocellular carcinoma who
cirrhosis diagnosis. Furthermore, the posttreatment parameters of the AFP level 1 tolica del Sacro Cuore, Rome, Italy. month after PEI and recurrence of HCC in the same liver segment were also 2 Divisione di Gastroenterologia, IRCCS Casa evaluated. Sollievo della Sofferenza, San Giovanni Rotondo #
## BACKGROUND. The objective of this study was to evaluate the indications for percutaneous ethanol injection (PEI) performed in a single session under general anesthesia for treating patients with cirrhosis and large (tumors ΟΎ 5 cm) hepatocellular carcinoma (HCC), and relevant survival curves. #
## Background: In japan, where liver transplantation has not been used to treat patients with hepatocellular carcinoma (hcc), percutaneous ethanol injection (pei) has been employed for those with small hccs that are not amenable to surgical resection. in the current study, the authors evaluated pei
For the treatment of small hepatocellular carcinoma (HCC), radiofrequency ablation (RFA) is in some centers considered a first-line therapeutic option. However, such a strategy is still under debate with regard to tumor and patient characteristics. In this single-center study we assessed the 5-year